Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor.

Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, Fichter M, Wang C, Liang S, Silva M, Kumari S, Mehta NK, Abraham W, Thai N, Li N, Wittrup KD, Irvine DJ.

Science. 2019 Jul 12;365(6449):162-168. doi: 10.1126/science.aav8692.

PMID:
31296767
2.

Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy.

Momin N, Mehta NK, Bennett NR, Ma L, Palmeri JR, Chinn MM, Lutz EA, Kang B, Irvine DJ, Spranger S, Wittrup KD.

Sci Transl Med. 2019 Jun 26;11(498). pii: eaaw2614. doi: 10.1126/scitranslmed.aaw2614.

PMID:
31243150
3.

Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.

Dréau D, Moore LJ, Wu M, Roy LD, Dillion L, Porter T, Puri R, Momin N, Wittrup KD, Mukherjee P.

Front Oncol. 2019 Apr 30;9:330. doi: 10.3389/fonc.2019.00330. eCollection 2019.

4.

Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models.

Rothschilds A, Tzeng A, Mehta NK, Moynihan KD, Irvine DJ, Wittrup KD.

Oncoimmunology. 2019 Feb 19;8(5):e1558678. doi: 10.1080/2162402X.2018.1558678. eCollection 2019.

PMID:
31069130
5.

What, Why, Where, and When: Bringing Timing to Immuno-Oncology.

Rothschilds AM, Wittrup KD.

Trends Immunol. 2019 Jan;40(1):12-21. doi: 10.1016/j.it.2018.11.003. Epub 2018 Dec 10. Review.

PMID:
30545676
6.

A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.

Kauke MJ, Tisdale AW, Kelly RL, Braun CJ, Hemann MT, Wittrup KD.

Mol Cancer Ther. 2018 Aug;17(8):1773-1780. doi: 10.1158/1535-7163.MCT-17-0645. Epub 2018 May 2.

7.

Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types.

Chen TF, Li KK, Zhu EF, Opel CF, Kauke MJ, Kim H, Atolia E, Wittrup KD.

J Mol Biol. 2018 Jun 8;430(12):1786-1798. doi: 10.1016/j.jmb.2018.04.021. Epub 2018 Apr 25.

8.

Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis.

Angelini A, Miyabe Y, Newsted D, Kwan BH, Miyabe C, Kelly RL, Jamy MN, Luster AD, Wittrup KD.

Nat Commun. 2018 Apr 13;9(1):1461. doi: 10.1038/s41467-018-03687-x.

9.

Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries.

Kelly RL, Le D, Zhao J, Wittrup KD.

J Mol Biol. 2018 Jan 5;430(1):119-130. doi: 10.1016/j.jmb.2017.11.008. Epub 2017 Nov 26.

10.

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, Wilbur DS, Fisher DR, Nartea M, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, Orcutt KD, Wittrup KD, Press OW.

Blood. 2018 Feb 8;131(6):611-620. doi: 10.1182/blood-2017-09-807610. Epub 2017 Nov 20.

11.

Nonspecificity in a nonimmune human scFv repertoire.

Kelly RL, Zhao J, Le D, Wittrup KD.

MAbs. 2017 Oct;9(7):1029-1035. doi: 10.1080/19420862.2017.1356528. Epub 2017 Sep 14.

12.

Antitumor Antibodies Can Drive Therapeutic T Cell Responses.

Wittrup KD.

Trends Cancer. 2017 Sep;3(9):615-620. doi: 10.1016/j.trecan.2017.07.001. Epub 2017 Jul 29. Review.

13.

Chaperone proteins as single component reagents to assess antibody nonspecificity.

Kelly RL, Geoghegan JC, Feldman J, Jain T, Kauke M, Le D, Zhao J, Wittrup KD.

MAbs. 2017 Oct;9(7):1036-1040. doi: 10.1080/19420862.2017.1356529. Epub 2017 Jul 26.

14.

An engineered protein antagonist of K-Ras/B-Raf interaction.

Kauke MJ, Traxlmayr MW, Parker JA, Kiefer JD, Knihtila R, McGee J, Verdine G, Mattos C, Wittrup KD.

Sci Rep. 2017 Jul 19;7(1):5831. doi: 10.1038/s41598-017-05889-7.

15.

Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.

Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NV, Larson SM.

J Nucl Med. 2017 Nov;58(11):1735-1742. doi: 10.2967/jnumed.117.193250. Epub 2017 Jul 13.

16.

Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.

Chen TF, Sazinsky SL, Houde D, DiLillo DJ, Bird J, Li KK, Cheng GT, Qiu H, Engen JR, Ravetch JV, Wittrup KD.

J Mol Biol. 2017 Aug 4;429(16):2528-2541. doi: 10.1016/j.jmb.2017.07.001. Epub 2017 Jul 8.

17.

Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins.

Yang NJ, Kauke MJ, Sun F, Yang LF, Maass KF, Traxlmayr MW, Yu Y, Xu Y, Langer RS, Anderson DG, Wittrup KD.

Nucleic Acids Res. 2017 Jul 27;45(13):7602-7614. doi: 10.1093/nar/gkx546.

18.

Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses.

Kwan BH, Zhu EF, Tzeng A, Sugito HR, Eltahir AA, Ma B, Delaney MK, Murphy PA, Kauke MJ, Angelini A, Momin N, Mehta NK, Maragh AM, Hynes RO, Dranoff G, Cochran JR, Wittrup KD.

J Exp Med. 2017 Jun 5;214(6):1679-1690. doi: 10.1084/jem.20160831. Epub 2017 May 4.

19.

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.

Smith TT, Moffett HF, Stephan SB, Opel CF, Dumigan AG, Jiang X, Pillarisetty VG, Pillai SPS, Wittrup KD, Stephan MT.

J Clin Invest. 2017 Jun 1;127(6):2176-2191. doi: 10.1172/JCI87624. Epub 2017 Apr 24.

20.

Biophysical properties of the clinical-stage antibody landscape.

Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Baruah H, Gray LT, Krauland EM, Xu Y, Vásquez M, Wittrup KD.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):944-949. doi: 10.1073/pnas.1616408114. Epub 2017 Jan 17.

21.

Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.

Sharkey B, Pudi S, Wallace Moyer I, Zhong L, Prinz B, Baruah H, Lynaugh H, Kumar S, Wittrup KD, Nett JH.

MAbs. 2017 Feb/Mar;9(2):257-268. doi: 10.1080/19420862.2016.1267090. Epub 2016 Dec 12.

22.

Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.

Tzeng A, Kauke MJ, Zhu EF, Moynihan KD, Opel CF, Yang NJ, Mehta N, Kelly RL, Szeto GL, Overwijk WW, Irvine DJ, Wittrup KD.

Cell Rep. 2016 Dec 6;17(10):2503-2511. doi: 10.1016/j.celrep.2016.11.020.

23.

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, O'Steen S, Orcutt KD, Wilbur DS, Wittrup KD, Press OW.

Cancer Res. 2016 Nov 15;76(22):6669-6679. doi: 10.1158/0008-5472.CAN-16-0571. Epub 2016 Sep 2.

24.

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ.

Nat Med. 2016 Dec;22(12):1402-1410. doi: 10.1038/nm.4200. Epub 2016 Oct 24.

25.

Target-independent variable region mediated effects on antibody clearance can be FcRn independent.

Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y, Wittrup KD.

MAbs. 2016 Oct;8(7):1269-1275. Epub 2016 Sep 9.

26.

Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library.

Traxlmayr MW, Kiefer JD, Srinivas RR, Lobner E, Tisdale AW, Mehta NK, Yang NJ, Tidor B, Wittrup KD.

J Biol Chem. 2016 Oct 21;291(43):22496-22508. Epub 2016 Aug 30.

27.

Design Principles for SuCESsFul Biosensors: Specific Fluorophore/Analyte Binding and Minimization of Fluorophore/Scaffold Interactions.

de Picciotto S, Dickson PM, Traxlmayr MW, Marques BS, Socher E, Zhao S, Cheung S, Kiefer JD, Wand AJ, Griffith LG, Imperiali B, Wittrup KD.

J Mol Biol. 2016 Oct 9;428(20):4228-4241. doi: 10.1016/j.jmb.2016.07.004. Epub 2016 Jul 21.

28.

Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).

Singh AP, Maass KF, Betts AM, Wittrup KD, Kulkarni C, King LE, Khot A, Shah DK.

AAPS J. 2016 Jul;18(4):861-75. doi: 10.1208/s12248-016-9904-3. Epub 2016 Mar 30.

29.

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.

Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM.

Science. 2016 Mar 4;351(6277):1078-83. doi: 10.1126/science.aad5788. Epub 2016 Feb 18.

30.

Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.

Maass KF, Kulkarni C, Betts AM, Wittrup KD.

AAPS J. 2016 May;18(3):635-46. doi: 10.1208/s12248-016-9892-3. Epub 2016 Feb 24.

31.

Generation of Fluorogen-Activating Designed Ankyrin Repeat Proteins (FADAs) as Versatile Sensor Tools.

Schütz M, Batyuk A, Klenk C, Kummer L, de Picciotto S, Gülbakan B, Wu Y, Newby GA, Zosel F, Schöppe J, Sedlák E, Mittl PRE, Zenobi R, Wittrup KD, Plückthun A.

J Mol Biol. 2016 Mar 27;428(6):1272-1289. doi: 10.1016/j.jmb.2016.01.017. Epub 2016 Jan 23.

PMID:
26812208
32.

Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S, Fung EK, Jungbluth A, Zanzonico PB, Carrasquillo JA, O'Donoghue J, Smith-Jones PM, Wittrup KD, Cheung NK, Larson SM.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):925-37. doi: 10.1007/s00259-015-3254-8. Epub 2015 Nov 24.

33.

A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.

Maass KF, Kulkarni C, Quadir MA, Hammond PT, Betts AM, Wittrup KD.

J Pharm Sci. 2015 Dec;104(12):4409-4416. doi: 10.1002/jps.24631. Epub 2015 Sep 7.

34.

A switchable yeast display/secretion system.

Van Deventer JA, Kelly RL, Rajan S, Wittrup KD, Sidhu SS.

Protein Eng Des Sel. 2015 Oct;28(10):317-25. doi: 10.1093/protein/gzv043. Epub 2015 Sep 1.

35.

Protein Engineering and Selection Using Yeast Surface Display.

Angelini A, Chen TF, de Picciotto S, Yang NJ, Tzeng A, Santos MS, Van Deventer JA, Traxlmayr MW, Wittrup KD.

Methods Mol Biol. 2015;1319:3-36. doi: 10.1007/978-1-4939-2748-7_1.

PMID:
26060067
36.

High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice.

Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vásquez M, Wittrup KD, Xu Y.

MAbs. 2015;7(4):770-7. doi: 10.1080/19420862.2015.1043503.

37.

Antibody-mediated neutralization of perfringolysin o for intracellular protein delivery.

Yang NJ, Liu DV, Sklaviadis D, Gui DY, Vander Heiden MG, Wittrup KD.

Mol Pharm. 2015 Jun 1;12(6):1992-2000. doi: 10.1021/mp500797n. Epub 2015 May 4.

38.

Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, Dranoff G, Wittrup KD.

Cancer Cell. 2015 Apr 13;27(4):489-501. doi: 10.1016/j.ccell.2015.03.004.

39.

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3320-5. doi: 10.1073/pnas.1416159112. Epub 2015 Mar 2.

40.

Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies.

Wang S, Mata-Fink J, Kriegsman B, Hanson M, Irvine DJ, Eisen HN, Burton DR, Wittrup KD, Kardar M, Chakraborty AK.

Cell. 2015 Feb 12;160(4):785-797. doi: 10.1016/j.cell.2015.01.027. Epub 2015 Feb 5.

41.

Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody.

Rouha H, Badarau A, Visram ZC, Battles MB, Prinz B, Magyarics Z, Nagy G, Mirkina I, Stulik L, Zerbs M, Jägerhofer M, Maierhofer B, Teubenbacher A, Dolezilkova I, Gross K, Banerjee S, Zauner G, Malafa S, Zmajkovic J, Maier S, Mabry R, Krauland E, Wittrup KD, Gerngross TU, Nagy E.

MAbs. 2015;7(1):243-54. doi: 10.4161/19420862.2014.985132.

42.

A graphene-based physiometer array for the analysis of single biological cells.

Paulus GL, Nelson JT, Lee KY, Wang QH, Reuel NF, Grassbaugh BR, Kruss S, Landry MP, Kang JW, Vander Ende E, Zhang J, Mu B, Dasari RR, Opel CF, Wittrup KD, Strano MS.

Sci Rep. 2014 Oct 31;4:6865. doi: 10.1038/srep06865.

43.

Tumor cells are dislodged into the pulmonary vein during lobectomy.

Yao X, Williamson C, Adalsteinsson VA, D'Agostino RS, Fitton T, Smaroff GG, William RT, Wittrup KD, Love JC.

J Thorac Cardiovasc Surg. 2014 Dec;148(6):3224-31.e1-5. doi: 10.1016/j.jtcvs.2014.06.074. Epub 2014 Jul 23.

44.

A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA.

Liu DV, Yang NJ, Wittrup KD.

Mol Ther Nucleic Acids. 2014 May 13;3:e162. doi: 10.1038/mtna.2014.14.

45.

Equilibrium and dynamic design principles for binding molecules engineered for reagentless biosensors.

de Picciotto S, Imperiali B, Griffith LG, Wittrup KD.

Anal Biochem. 2014 Sep 1;460:9-15. doi: 10.1016/j.ab.2014.04.036. Epub 2014 May 9.

46.

CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Bak SP, Barnkob MS, Wittrup KD, Chen J.

Cancer Immunol Res. 2013 Dec;1(6):393-401. doi: 10.1158/2326-6066.CIR-13-0109. Epub 2013 Sep 20.

47.

Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.

Yao X, Choudhury AD, Yamanaka YJ, Adalsteinsson VA, Gierahn TM, Williamson CA, Lamb CR, Taplin ME, Nakabayashi M, Chabot MS, Li T, Lee GS, Boehm JS, Kantoff PW, Hahn WC, Wittrup KD, Love JC.

Integr Biol (Camb). 2014 Apr;6(4):388-98. doi: 10.1039/c3ib40264a. Epub 2014 Feb 13.

48.

Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation.

Van Deventer JA, Wittrup KD.

Methods Mol Biol. 2014;1131:151-81. doi: 10.1007/978-1-62703-992-5_10.

PMID:
24515465
49.

Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.

Schmidt MM, Townson SA, Andreucci AJ, King BM, Schirmer EB, Murillo AJ, Dombrowski C, Tisdale AW, Lowden PA, Masci AL, Kovalchin JT, Erbe DV, Wittrup KD, Furfine ES, Barnes TM.

Structure. 2013 Nov 5;21(11):1966-78. doi: 10.1016/j.str.2013.08.022. Epub 2013 Oct 10.

50.

Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool.

Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, Torrey J, Thomas J, Bobrowicz P, Vásquez M, Wittrup KD, Krauland E.

Protein Eng Des Sel. 2013 Oct;26(10):663-70. doi: 10.1093/protein/gzt047. Epub 2013 Sep 17.

PMID:
24046438

Supplemental Content

Loading ...
Support Center